A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

NEW YORK – CAR T-cell therapy developer Cargo Therapeutics earlier this week announced it will be bought by Concentra Biosciences.

The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.

The funds will help the firm advance copper-based radioligand therapies and imaging agents in prostate, neuroendocrine, and breast cancers.